{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:32:02Z","timestamp":1793356322646,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.anai.2026.07.022","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:46:29Z","timestamp":1785167189000},"page":"595-601.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab effectiveness and safety in patients with chronic rhinosinusitis with nasal polyps"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0745-2379","authenticated-orcid":false,"given":"Anju T.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeharu","family":"Fujieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Buchheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein E.","family":"Cornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Almansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl S29","key":"10.1016\/j.anai.2026.07.022_bib0001","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"9","key":"10.1016\/j.anai.2026.07.022_bib0002","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.anai.2026.07.022_bib0003","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/all.12983","article-title":"Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre","volume":"72","author":"van der Veen","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2026.07.022_bib0004","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"4","key":"10.1016\/j.anai.2026.07.022_bib0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2026.07.022_bib0006","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"issue":"10209","key":"10.1016\/j.anai.2026.07.022_bib0007","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2026.07.022_bib0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40290-022-00456-6","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharm Med"},{"issue":"2","key":"10.1016\/j.anai.2026.07.022_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/picr.PICR_36_18","article-title":"Real world evidence (RWE) - are we (RWE) ready?","volume":"9","author":"Suvarna","year":"2018","journal-title":"Perspect Clin Res"},{"issue":"2","key":"10.1016\/j.anai.2026.07.022_bib0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/all.70032","article-title":"Two-year turning point with dupilumab in CRSwNP: control, remission, and tapering dosage","volume":"81","author":"De Corso","year":"2025","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2026.07.022_bib0011","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/all.15134","article-title":"Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"77","author":"van der Lans","year":"2022","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.anai.2026.07.022_bib0012","doi-asserted-by":"crossref","first-page":"00085","DOI":"10.1183\/23120541.00085-2022","article-title":"AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"8","author":"Siddiqui","year":"2022","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.anai.2026.07.022_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2024.104596","article-title":"Baseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registry","volume":"46","author":"Fujieda","year":"2025","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.anai.2026.07.022_bib0014","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/JAA.S519901","article-title":"Comparing baseline characteristics of patients with chronic rhinosinusitis with nasal polyps with and without asthma in the AROMA registry","volume":"18","author":"Peters","year":"2025","journal-title":"J Asthma Allergy"},{"issue":"7","key":"10.1016\/j.anai.2026.07.022_bib0015","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/lary.32162","article-title":"Dupilumab monthly dose de-escalation maintains efficacy in CRSwNP: a two-year real-world study","volume":"135","author":"De Corso","year":"2025","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.anai.2026.07.022_bib0016","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/alr.22944","article-title":"Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps","volume":"12","author":"Hellings","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"10.1016\/j.anai.2026.07.022_bib0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/lary.29888","article-title":"Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis","volume":"132","author":"Han","year":"2022","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1016\/j.anai.2026.07.022_bib0018","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"issue":"2","key":"10.1016\/j.anai.2026.07.022_bib0019","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/thx.47.2.76","article-title":"Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials","volume":"47","author":"Juniper","year":"1992","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.anai.2026.07.022_bib0020","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:32:31Z","timestamp":1793352751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626003595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1081120626003595"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.022","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab effectiveness and safety in patients with chronic rhinosinusitis with nasal polyps","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}